ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody

PURPOSE: Advances in our understanding of the contribution of aberrant glycosylation to the pro-oncogenic signaling and metastasis of tumor cells have reinvigorated the development of mucin-targeted therapies. Here, we validate the tumor-targeting ability of a novel monoclonal antibody (mAb), AR9.6,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sai Kiran, Mack, Kyeara N., Piersigilli, Alessandra, Pourat, Jacob, Edwards, Kimberly J., Keinänen, Outi, Jiao, Maria S., Zhao, Huiyong, White, Brandy, Brooks, Cory L., de Stanchina, Elisa, Madiyalakan, Madi R., Hollingsworth, Michael A., Radhakrishnan, Prakash, Lewis, Jason S., Zeglis, Brian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898287/
https://www.ncbi.nlm.nih.gov/pubmed/34907079
http://dx.doi.org/10.1158/1078-0432.CCR-21-1798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898287/
https://www.ncbi.nlm.nih.gov/pubmed/34907079
http://dx.doi.org/10.1158/1078-0432.CCR-21-1798

Ejemplares similares